

Silvia Pomella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5749359/publications.pdf>

Version: 2024-02-01

33
papers

845
citations

687363

13
h-index

642732

23
g-index

37
all docs

37
docs citations

37
times ranked

1489
citing authors

#	ARTICLE	IF	CITATIONS
1	New Insights on the Nuclear Functions and Targeting of FAK in Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1998.	4.1	19
2	Epigenetic remodelling in human hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 107.	8.6	21
3	MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression. <i>Frontiers in Oncology</i> , 2022, 12, 835642.	2.8	5
4	Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114410.	5.5	15
5	Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma. <i>Nature Communications</i> , 2021, 12, 192.	12.8	33
6	Small heat-shock protein HSPB3 promotes myogenesis by regulating the lamin B receptor. <i>Cell Death and Disease</i> , 2021, 12, 452.	6.3	16
7	Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in <i>Ávitro</i> and in <i>Ávivo</i> , the alveolar phenotype subtype. <i>International Journal of Radiation Biology</i> , 2021, 97, 943-957.	1.8	13
8	Abstract 47: Identification of first-in-class KDM3B inhibitors that suppress PAX3-FOXO1 oncogene activity in fusion positive rhabdomyosarcoma. , 2021, , .		0
9	SNAI2-Mediated Repression of <i>BIM</i> Protects Rhabdomyosarcoma from Ionizing Radiation. <i>Cancer Research</i> , 2021, 81, 5451-5463.	0.9	13
10	MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10671.	4.1	14
11	DNMT3A and DNMT3B Targeting as an Effective Radiosensitizing Strategy in Embryonal Rhabdomyosarcoma. <i>Cells</i> , 2021, 10, 2956.	4.1	18
12	Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 364.	8.6	15
13	Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery. <i>Nature Biotechnology</i> , 2020, 38, 50-55.	17.5	51
14	FAK Signaling in Rhabdomyosarcoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8422.	4.1	8
15	CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas. <i>Frontiers in Pharmacology</i> , 2020, 11, 1230.	3.5	20
16	Miswired Enhancer Logic Drives a Cancer of the Muscle Lineage. <i>IScience</i> , 2020, 23, 101103.	4.1	26
17	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 977-983.	2.8	49
18	The CRISP(Y) Future of Pediatric Soft Tissue Sarcomas. <i>Frontiers in Chemistry</i> , 2020, 8, 178.	3.6	3

#	ARTICLE	IF	CITATIONS
19	Abstract A08: Development of FGFR4-specific chimeric antibody receptor (CAR) T cell and bispecific T cell engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy. , 2020, , .		1
20	Abstract 4175: Identification of novel inhibitors of the PAX3-FOXO1 fusion oncogene in rhabdomyosarcoma. , 2020, , .		0
21	Abstract B35: Liaison between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in fusion-negative rhabdomyosarcoma. , 2020, , .		0
22	Chemical genomics reveals histone deacetylases are required for core regulatory transcription. Nature Communications, 2019, 10, 3004.	12.8	107
23	Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma. Nature Genetics, 2019, 51, 1714-1722.	21.4	113
24	Notch Signaling in Pediatric Soft Tissue Sarcoma. , 2018, , 277-312.		1
25	Abstract 4139: SNAI2 inhibition promotes myogenic differentiation and prevents tumorigenic features of embryonal rhabdomyosarcoma. , 2018, , .		0
26	PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discovery, 2017, 7, 884-899.	9.4	221
27	Abstract 2065: Targeting the crosstalk between MET and Notch signaling in Rhabdomyosarcoma. , 2017, , .		0
28	Abstract 1922: miR-301 expression is deregulated in rhabdomyosarcoma. Cancer Research, 2016, 76, 1922-1922.	0.9	0
29	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2015, 8, 125.	17.0	28
30	MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma. Clinical Epigenetics, 2015, 7, 82.	4.1	33
31	Abstract 1772: Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL). , 2012, , .		0
32	The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood, 2011, 118, 76-76.	1.4	1
33	ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112. Blood, 2011, 118, 2574-2574.	1.4	0